Johnson & Johnson (JNJ) | Stock Overview & Key Data
Johnson & Johnson Performance Comparison
Stock Range
Today's Range
Low: $166.37
High: $168.78
on July 29, 2025
52 Week Range
Low: $140.68
High: $169.99
on January 10, 2025
on July 24, 2025
All-Time High: $186.69 on April 25, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$400.3B
EPS
9.34
P/E Ratio (TTM)
17.80
Forward P/E
15.68
P/B Ratio
5.10
PEG Ratio
15.68
Div. Yield
2.47%
ROE
30.21%
Beta
0.400
Debt to Equity
64.69
Financial Highlights
Profitability
Gross Margin
67.87%
Operating Margin
28.65%
Profit Margin
25.00%
Returns and Earnings
Return on Assets (TTM)
7.61%
Return on Equity (TTM)
30.21%
EBITDA
$31.8B
Net Income (TTM)
$22.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$37.65
Quarterly Revenue Growth (YoY)
5.80%
Quarterly Earnings Growth (YoY)
18.20%
Dividend Information
Last 12-Month Dividend
$3.72
Current Dividend Yield
2.47%
3-Year Average Dividend Yield
0.75%
3-Year Average Annual Dividend
$3.97
3-Year Total Dividends
$11.92
Ex-Dividend Date
February 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson JNJ | 400.31B Mega-cap | 0.11% | 10.06% | 7.83% | 11.22% | 16.73% | 2.42% | -1.75% | 13.13% |
| Eli Lilly and LLY | 729.58B Mega-cap | -1.74% | -2.13% | -13.81% | -5.12% | -1.94% | -5.16% | 153.20% | 398.89% |
| AbbVie ABBV | 336.11B Mega-cap | 2.20% | 3.02% | -1.18% | 9.11% | 6.56% | 1.02% | 38.53% | 105.79% |
| Merck & Co MRK | 212.71B Mega-cap | 1.25% | 4.38% | -2.46% | -15.92% | -16.68% | -28.27% | -5.47% | 6.88% |
| Amgen AMGN | 162.01B Large-cap | -0.70% | 8.72% | 5.20% | 7.77% | 17.08% | -9.11% | 23.27% | 26.12% |
| Gilead Sciences GILD | 144.55B Large-cap | 3.69% | 3.03% | 9.62% | 19.50% | 24.33% | 48.80% | 86.99% | 64.72% |
Ownership & Short Interest
Insider Ownership
0.06%
Institutional Ownership
74.02%
Shares Short
18M
Short Ratio
2.21
Short % of Shares Outstanding
0.76%
Average 10-Day Volume
10M
Average 90-Day Volume
9M
Johnson & Johnson Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Johnson & Johnson would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JNJ's 52-week high and low?
- In the last 52 weeks, Johnson & Johnson reached a high of $169.99 (on July 24, 2025) and a low of $140.68 (on January 10, 2025).
- What is the market cap and P/E ratio for JNJ?
- Curious about Johnson & Johnson's size and valuation? Its market capitalization stands at 400.31B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.80, and the forward P/E (looking ahead) is 15.68.
- Does JNJ pay dividends? If so, what's the yield?
- Yes, Johnson & Johnson is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.47%, and the company has paid an average of $3.97 per share annually over the past 3 years.
- Who are Johnson & Johnson's main competitors or similar companies to consider before investing?
When looking at Johnson & Johnson, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY729.58B Healthcare Drug Manufacturers - General -5.16% 153.20% AbbVie
ABBV336.11B Healthcare Drug Manufacturers - General 1.02% 38.53% Merck & Co
MRK212.71B Healthcare Drug Manufacturers - General -28.27% -5.47% Amgen
AMGN162.01B Healthcare Drug Manufacturers - General -9.11% 23.27% Gilead Sciences
GILD144.55B Healthcare Drug Manufacturers - General 48.80% 86.99% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Johnson & Johnson? (e.g., ROE, Debt/Equity)
- To get a sense of Johnson & Johnson's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.21%, the Debt to Equity ratio from the most recent quarter is 64.69, and its Gross Profit Margin stands at 67.87%.
- What is the recent revenue and earnings growth for JNJ?
- Looking at Johnson & Johnson's growth, its revenue over the trailing twelve months (TTM) was $91B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.80%, and quarterly earnings saw a YoY growth of 18.20%.
- How much of JNJ stock is held by insiders and institutions?
- Wondering who owns Johnson & Johnson stock? Company insiders (like executives and directors) hold about 0.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 74.02%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.